Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J N Joyce

Showing results (1-10 of 86) with videos related to

Pageof 9
Sort By:
Clinical Neuropharmacology|January 1, 1992
Monoamine receptors, limbic pathology and schizophreniaJ N Joyce
Synapse (New York, N.Y.)|March 17, 2001
D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal periodJ N Joyce
Pharmacology & Therapeutics|October 2, 2001
Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugsJ N Joyce
Neuroscience and Biobehavioral Reviews|January 1, 1983
Multiple dopamine receptors and behaviorJ N Joyce
Psychopharmacology|January 1, 1993
The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrineJ N Joyce
Experimental Neurology|September 1, 1991
Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine systemJ N Joyce
Experimental Neurology|September 1, 1991
Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. II. Effects of 6-hydroxydopamine or colchicine microinjections into the VTA or reserpine treatmentJ N Joyce
Brain Research|January 8, 1993
Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease casesJ N Joyce
Progress in Brain Research|January 1, 1990
Differential regulation of striatal dopamine D1 and D2 receptor systems in Parkinson's disease and effects of adrenal medullary transplantJ N Joyce, H Hurtig
Journal of Neural Transmission. Parkinson'S Disease and Dementia Section|January 1, 1993
Substance P receptors are differentially affected in Parkinson's and Alzheimer's diseaseL Rioux, J N Joyce
Pageof 9

Showing results (1-10 of 86) with videos related to

Sort By:
Pageof 9
Clinical Neuropharmacology|January 1, 1992
Monoamine receptors, limbic pathology and schizophreniaJ N Joyce
Synapse (New York, N.Y.)|March 17, 2001
D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal periodJ N Joyce
Pharmacology & Therapeutics|October 2, 2001
Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugsJ N Joyce
Neuroscience and Biobehavioral Reviews|January 1, 1983
Multiple dopamine receptors and behaviorJ N Joyce
Psychopharmacology|January 1, 1993
The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrineJ N Joyce
Experimental Neurology|September 1, 1991
Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine systemJ N Joyce
Experimental Neurology|September 1, 1991
Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. II. Effects of 6-hydroxydopamine or colchicine microinjections into the VTA or reserpine treatmentJ N Joyce
Brain Research|January 8, 1993
Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease casesJ N Joyce
Progress in Brain Research|January 1, 1990
Differential regulation of striatal dopamine D1 and D2 receptor systems in Parkinson's disease and effects of adrenal medullary transplantJ N Joyce, H Hurtig
Journal of Neural Transmission. Parkinson'S Disease and Dementia Section|January 1, 1993
Substance P receptors are differentially affected in Parkinson's and Alzheimer's diseaseL Rioux, J N Joyce
Pageof 9